Design and evaluation of bi-layered tablet of Ramipril and hydrochlorothiazide for the Treatment of hypertension

Abstract

Hypertension is a widespread cardiovascular disease that requires effective management through combination therapy. The complexity of hypertension necessitates a multifaceted approach, often involving the concurrent administration of multiple antihypertensive agents. This study aims to design, formulate, and evaluate bi-layered tablets of Ramipril and Hydrochlorothiazide, leveraging the benefits of sequential drug release and stability enhancement. The bi-layer tablet formulation comprises an immediate-release layer for rapid therapeutic onset and a sustained-release layer for prolonged plasma drug concentration, thereby providing a synergistic effect in reducing blood pressure. Ramipril, an angiotensin-converting enzyme (ACE) inhibitor, and Hydrochlorothiazide, a diuretic, are commonly used in combination therapy for the treatment of hypertension. The rationale behind this combination lies in their complementary mechanisms of action, which together provide a more effective reduction in blood pressure than either drug alone. The proposed formulation utilizes a range of excipients, including Pregelatinized Starch, Microcrystalline Cellulose, Lactose Anhydrate, Sodium Bicarbonate, Sodium Stearyl Fumarate, Cross Carmellose Sodium, Talc, Povidone, and Hydroxy Propyl Methyl Cellulose (HPMC), carefully selected to achieve the desired drug release profiles. The bi-layer tablet technology offers several advantages, including the ability to separate two incompatible drugs, provide sequential release of two drugs in combination, and achieve sustained release of one drug while the other provides immediate therapeutic effects. This study focuses on formulating and characterizing monolayer and bilayer tablets to enhance stability, improve patient compliance, and provide a synergistic therapeutic effect. The proposed research will involve the optimization of formulation variables, such as the ratio of excipients and the compression force, to achieve the desired drug release profiles. The tablets will be evaluated for various physicochemical parameters, including hardness, friability, weight variation, and content uniformity. In vitro drug release studies will be conducted to assess the release profiles of Ramipril and Hydrochlorothiazide from the bi-layer tablets. By developing a bi-layer tablet formulation of Ramipril and Hydrochlorothiazide, this study aims to provide a more effective and convenient treatment option for patients with hypertension, ultimately improving patient outcomes and quality of life.

Key Highlights:

1. Bi-layer tablet formulation for sequential release of Ramipril and Hydrochlorothiazide.
2. Immediate-release layer for rapid therapeutic onset.
3. Sustained-release layer for prolonged plasma drug concentration.
4. Excipient selection for enhanced stability and drug release.
5. Optimization of formulation variables for desired drug release profiles.
6. Evaluation of physicochemical parameters and in vitro drug release profiles.